❈Bookmess Niche Ad❈

ASCO 2022 Conference Abstracts - Major Data Readouts

By havensmith at 20 Days Ago • 0 collector • 16 pageviews

A poster session was presented that indicated an indirect comparison of TAK-788 vs. real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The intervention TAK 788 is produced by Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. TAK 788 is a small molecule, and in the clinical trial study - nct02716116, a total of 99 patients were enrolled.

Requires login to continue

Log in
Link Exchange:
Sites ranked above 100,000 - $10/month

1. NairaLast Forum | NairaLast.com
2. APPTUNEZ.com
3. SEO Site Search
4. PlentyOfSale.com
5. AfriqueModels.com
6. Facekobo.com
7. IDeYsell.com


Whatsapp: whatsapp.com/KGILRGmOfjL9TfjkN9QPoY


ABOUT BOOKMESS

1. Bookmess is a content site for traffic generation and distribution to websites.
2. Bookmess content posters are responsible for the contents of their post.
3. Readers are responsible for their actions including reaching out and contacting posters.
4. If you find any post offensive [email protected]
5. Bookmess.com reserve the right to delete your post or ban/delete your profile if you are found to have contravened its rules.
6. You are responsible for any actions taken on Bookmess.com.
7. Bookmess does not endorse any particular content on its website.